


Interleukin-6 blockade with tocilizumab reduces immune checkpoint inhibitor-induced colitis and/or arthritis



Authors: Rikke B. Holmstroem, Ole H. Nielsen, Søren Jacobsen, Lene B. Riis, Susann Theile, Jacob T. Bjerrum, Peter Vilmann, Julia S. Johansen, Mogens K. Boisen, Rikke L. Eefsen, MD, Inge Marie Svane, Dorte L. Nielsen, and Inna M. Chen.

Correspondence: Inna.Chen@regionh.dk

In brief: Interleukin-6 blockade with tocilizumab reduced immune checkpoint inhibitor-induced colitis and/or arthritis in 16 of 19 (84%) patients. Half of the patients were able to continue checkpoint inhibitor treatment during tocilizumab treatment.